Biosimilar Newsletter Archive

  1. 01.29.26 -- The Latest In Upstream HCP Mitigation 1/29/2026
    01/29/26 Biosimilar Development Newsletter
  2. 01.15.26 -- SUS Insufficient For 40% Of Biopharma 1/15/2026
    01/15/26 Biosimilar Development Newsletter
  3. 01.08.26 -- What 2025 FDA Warning Letters Tell Us About GMP Compliance 1/8/2026
    01/08/26 Biosimilar Development Newsletter
  4. 12.18.25 -- Why Your MVP And Its Evolution Matters To Manufacturing 12/18/2025
    12/18/25 Biosimilar Development Newsletter
  5. 12.11.25 -- Indian Biosimilar Companies Are Poised To Succeed In The Global Market 12/11/2025
    12/11/25 Biosimilar Development Newsletter
  6. 12.04.25 -- What You Need To Know About The Access Consortium Pathway 12/4/2025
    12/04/25 Biosimilar Development Newsletter
  7. 12.02.25 -- Your trusted filters made closer to you – try by yourself! 12/2/2025

    12/02/25 Biosimilar Development Newsletter

  8. 11.26.25 -- FDA Biosimilars Guidance Reveals Reliance On Tox & PK 11/26/2025
    11/26/25 Biosimilar Development Newsletter
  9. 11.20.25 -- Optimize Formulation And Integrity Workflows 11/20/2025
    11/20/25 Biosimilar Development Newsletter
  10. 11.20.25 -- Your Biosimilar, Your Journey 11/20/2025
    11/20/25 Biosimilar Development Newsletter